



You have the Power to Improve Outcomes.

Wounds with <50% area reduction by week 4 are **significantly less likely to close**.^{1,2}

At 4 Weeks, it's Time to Move to Advanced Therapies.



It's **UP** to you.

MIMEDX

TIME'S UP.


At 4 Weeks, the Healing Trajectory is Clear

Wounds that achieve **less than 50% area reduction after four weeks** of standard of care (SOC) are **unlikely to close without escalation**.¹

Clinical evidence shows these wounds have:
Only a 9% Chance of Closure
by 12 weeks if SOC is continued alone²

When Healing Fails to Progress, Risk Accelerates

- Non-healing **diabetic foot ulcers (DFUs)** account for nearly 85% of non-traumatic lower-extremity amputations³
- Stalled wounds have a **significantly increased risk of infection** and the consequences are devastating:^{4,5}



Yet Despite Clear Evidence, Escalation Often Occurs Too Late.

- Only **13%** of clinicians frequently use advanced wound therapies⁸
- Fewer than **2%** of wounds ever receive a skin substitute - often not until **14 weeks into care**⁹

STEP UP.

It's Time for a **Change**



Critical, Covered and Clinically Validated

- Society guidelines identify the 4-week healing milestone as a key predictor of outcomes, with CMS LCD coverage and RCT and Medicare real-world evidence supporting skin substitute use in indicated DFU and VLU.^{1,10,11}

The Proof is in the Outcomes:



Know when **TIME'S UP** and **STEP UP**
to Advanced Wound Care

The MIMEDX Advantages

Access

- Broad coverage: **300M+ lives covered** by commercial insurance, Medicare, Medicare Advantage and Medicaid for MIMEDX products
- **MIMEDX Connect:** An online access platform providing real-time coverage insights, benefit verification, and site-of-care-specific reimbursement support.
- **Dedicated reimbursement and access team**, simplifying coverage and claims processes, ensuring patients get timely access to MIMEDX therapies
- **Easy ordering** and **fast delivery** options

Evidence

- **Robust clinical and scientific evidence** in placental-based allografts
- **Most level 1 evidence:** 9 published RCTs²⁻¹¹
 - **40+ clinical and scientific papers**
 - **Ongoing studies** including a current RCT for EPIEFFECT®
 - This **strong body of evidence** was instrumental in securing **LCD coverage** for EPIFIX® and EPICORD®

Operational Benefits

- **Ready-to-use** with no thawing or prep required
- **5-year** room temperature shelf-life reduces waste and eases logistics
- **Terminally sterilized** for an additional level of safety
- **Available in a multiple of configurations and sizes** for various wound types - means less graft wastage and more efficiency

REFERENCES: 1. Armstrong DG, et al. J Wound Care. 2021;30(Sup7):S5-S16. 2. Sheehan, et al. Diabetes Care. 2003;26(6):1879-1882. 3. Clegg DJ, et al. Plast Reconstr Surg Glob Open. 2023;11(11):e5383. 4. Maderal AD, et al. Hosp Pract (1995). 2012;40(3):102-115. 5. Lavery LA, et al. Diabetes Care. 2006;29(6):1288-1293. 6. Armstrong DG, et al. J Foot Ankle Res. 2020;13(1):16. 7. Tettlback WH, et al. J Wound Care. 2022;31(Sup2):S10-S31. 8. Mahoney K. HCPs' attitudes regarding current wound care treatments. Wound Care Today. <https://www.woundcare-today.com/journals/issue/wound-care-today/article/hcps-attitudes-regarding-current-wound-care-treatments>. Published December 2025. Accessed January 5, 2026. 9. Fife C. B.R.I.D.G.E. TO DATA and the US Wound Registry. US Wound Registry. <https://carolinefifemd.com/2020/09/01/b-r-i-d-g-e-to-data-and-the-us-wound-registry/>. Published September 1, 2020. Accessed December 18, 2025. 10. Chen P, et al. Diabetes Metab Res Rev. 2024;40(3):e3644. 11. CMS Local Coverage Determinations (LCDs) for Skin Substitute Grafts / Cellular & Tissue-Based Products (DFUs & VLU), Medicare Coverage Database (L39764 and related MAC LCDs). 12. BioMedGPS — SmartTRAK. Q422 and FY22 CTP Site of Care. <https://www.smarttrak.com>. Accessed June 15, 2023. 13. Zelen CM, et al. Int Wound J. 2013;10(5):502-507. 14. Zelen CM, et al. J Wound Care. 2013; 22(7):347-351. 15. Zelen CM, et al. Wound Medicine. 2014;4:1-4. 16. Zelen CM, et al. Int Wound J. 2014;11(2):122-128. 17. Zelen CM, et al. Int Wound J. 2015;12(6):724-732. 18. Zelen CM, et al. Int Wound J. 2016;13(2):272-282. 19. Tettlback WH, et al. Int Wound J. 2019;16(1):122-130. 20. Serena TE, et al. Wound Repair Regen. 2014;22(6):688-693. 21. Bianchi C, et al. Int Wound J. 2018;15(1):114-122. 22. Bianchi C, et al. Int Wound J. 2019;16(3):761-767.

To find out more about MIMEDX products:



LEARN MORE

CONTACT US: Scan
the code or visit
mimedx.com/contact/



Please Call: 866.477.4219



Email: customerservice@mimedx.com